Leerink Partners analyst, Joseph Schwartz, reiterated his Outperform rating on shares of Ultragenyx Pharma (NASDAQ: RARE) as he believes triheptanoin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE